 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
20 News |  |
- | Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Journal: Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination. (Pubmed Central) - Feb 26, 2022
The genotoxic assay spotted that Simvastatin produced less damage to DNA with the threshold of 500μg/ml whereas Sitagliptin significantly damage above the 250μg/mL, However, combination of drugs produced lesser damage than Sitagliptin alone. The findings concluded a non-genotoxic combination of sitagliptin and simvastatin which possess a least cytotoxic potential suggesting the safe use of the combination both in T2DM and CHD.
- | Cholib (fenofibrate/simvastatin) / AbbVie, Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Review, Journal: Vascular AMPK: enhancer, brake or both? (Pubmed Central) - Mar 30, 2021
The vascular protective effects of certain anti-diabetic (metformin and sitagliptin) or lipid-lowering (simvastatin and fenofibrate) therapeutic agents, of active components of Chinese medicinal herbs (resveratrol and berberine) and of pharmacological agents (AICAR, A769662 and PT1) have been attributed to the activation of AMPK (in endothelial cells, vascular smooth muscle cells and/or perivascular adipocytes), independently of changes in the metabolic profile (eg glucose tolerance and/or plasma lipoprotein levels), leading to improved endothelium-derived nitric oxide-mediated vasodilatation and attenuated endothelium-derived cyclooxygenase-dependent vasoconstriction...Therefore, AMPK activation is not necessarily beneficial in terms of endothelial function. The contribution of endothelial AMPK in the regulation of vascular tone, in particular in the microvasculature where EDH plays a more important role, remains to be characterized.
- || Clinical, Journal: Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects. (Pubmed Central) - Jun 5, 2020
All treatments were well tolerated. The lack of clinically meaningful pharmacokinetic interactions demonstrates that ertugliflozin can be coadministered safely with sitagliptin, metformin, glimepiride, or simvastatin without any need for dose adjustment.
- | simvastatin / Generic mfg., Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Journal: Epidemiology of Acute Pancreatitis in Southern Israel: A Retrospective Study. (Pubmed Central) - May 23, 2020
Furthermore, drug-induced pancreatitis is a common etiology, with disothiazide being the most common drug associated with pancreatitis followed by ACE-Inhibitors, sitagliptin, and simvastatin. Recurrence of pancreatitis is common in this geographic area, and older age, advanced CTSI grading, bilateral pleural effusion, and being single are all poor prognostic predictive factors.
- Juvisync (sitagliptin/simvastatin) / Merck (MSD), Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion: Glucagon-like Peptide (GLP) Utilization and Safety (clinicaltrials.gov) - Feb 5, 2014
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Recurrence of pancreatitis is common in this geographic area, and older age, advanced CTSI grading, bilateral pleural effusion, and being single are all poor prognostic predictive factors. Active, not recruiting --> Completed
- Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Monotherapy: A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266) (clinicaltrials.gov) - Nov 24, 2013
P3, N=297, Terminated, Sponsor: Merck
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Merck terminated the study for business reasons in November 2013.
- Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Monotherapy: A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266) (clinicaltrials.gov) - Nov 24, 2013
P3, N=297, Terminated, Sponsor: Merck
Active, not recruiting --> Terminated; Merck terminated the study for business reasons in November 2013. N=750 --> 297
- Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Trial completion, Monotherapy: A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312) (clinicaltrials.gov) - Jun 17, 2013
P3, N=42, Completed, Sponsor: Merck
N=750 --> 297 Active, not recruiting --> Completed
- | Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Enrollment change, Monotherapy: sitagliptin +simvastatin coadministration safety study (EUDRACT) - Dec 4, 2012
P3, N=750, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Active, not recruiting --> Completed N=40 --> 750
- Juvisync (sitagliptin/simvastatin) / Merck (MSD)
New P3 trial, Monotherapy: A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312) (clinicaltrials.gov) - Oct 4, 2012
P3, N=42, Completed, Sponsor: Merck
- || Juvisync (sitagliptin/simvastatin) / Merck (MSD)
New P3 trial, Monotherapy: sitagliptin +simvastatin coadministration safety study (EUDRACT) - Sep 27, 2012
P3, N=750, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Juvisync (sitagliptin/simvastatin) / Merck (MSD)
Monotherapy: A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266) (clinicaltrials.gov) - Sep 3, 2012
P3, N=297, Terminated, Sponsor: Merck